Nasdaq |
FDA clears Teva asthma med (TEVA)
Seeking Alpha (registration) The FDA approves Teva Pharmaceutical Industries' (NYSE:TEVA) ProAir RespiClick (albuterol sulfate) inhalation powder for the treatment or prevention of bronchospasm in patients at least 12 years old with reversible obstructive airway disease and for … Teva Announces FDA Approval of ProAir® RespiClick Teva Announces FDA Approval of ProAir(R) RespiClick |
View full post on asthma – Google News